Navigation Links
Genetics linked to leukemia treatment success rate in children

Genes may be at the root of how children react to cancer treatments.// A new study by the researchers funded by American Society of Hematology says that personalized medicine based on the genetic makeup of children may yield better results in treating childhood leukemia.

Researchers had looked into the records of 246 children suffering from acute lymphoblastic leukemia (ALL). The patients were divided into a high-risk group and a low risk group to decide on the intensity of therapy.

Acute lymphoblastic leukemia (ALL) is a form of cancer that affects the lymphocyte producing cells. In ALL, there is an accumulation of lymphocyte precursor cells, also called blast cells, in the bone marrow.

The researchers had used a process called genotyping, in which DNA drawn from the blood of the patients were screened for common genetic variations. The researchers had narrowed down their study on gene codes for enzymes, which are involved in the metabolism and reaction to chemotherapy drugs used in treating cancer.

The results had showed that for children in the lower risk group, having TYMS 3/3 genotype may be a risk factor for the disease. For the children in the high-risk group, GSTM1 non-null genotype was responsible for treatment failure and recurrence of the disease.

The research will be published in the new edition of the journal Blood.
'"/>




Page: 1

Related medicine news :

1. Genetics and cholesterol levels
2. Genetics helps in attacking cancer
3. Alcoholism Influenced By Both Genetics & Family Environment
4. Genetics Has A Major Role To Play In Body Shape.
5. Revolution in Genetics to Open Avenues for Treating Cancer
6. Faster way of producing Bird flu vaccine using Reverse Genetics
7. Genetics of Ageing with Preserved Mental Capacity.
8. Generation Scotland To Examine Relation Between Lifestyle, Genetics and Health
9. Genetics Might BE The Basis For Chronic Fatigue Syndrome
10. Personalized Genetics: Unraveling the Secret Code to Good Health.
11. Genetics Of Mental Retardation
Post Your Comments:
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 1Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 3Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 4Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 1InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 2InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 3InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 4InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 6InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 7InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 8InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 9InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 10InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 11InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 12InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 13Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 1Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 2Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 3Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 4Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 5Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 6Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 7